Clinical Trials Logo

Stage IIA Anal Cancer AJCC v8 clinical trials

View clinical trials related to Stage IIA Anal Cancer AJCC v8.

Filter by:
  • None
  • Page 1

NCT ID: NCT05130073 Completed - Clinical trials for Anal Squamous Cell Carcinoma

4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer

Start date: July 31, 2019
Phase:
Study type: Observational

This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.

NCT ID: NCT04166318 Recruiting - Clinical trials for Anal Canal Cloacogenic Carcinoma

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Start date: January 2, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

NCT ID: NCT03690921 Completed - Clinical trials for Anal Canal Squamous Cell Carcinoma

Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial

Start date: November 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer. LET-IMPT is a type of radiation therapy that uses high energy proton "beamlets" to "paint" the radiation dose into the target and may help to kill tumor cells and shrink tumors. Giving LET-IMPT and standard chemotherapy may work better in treating patients with anal canal squamous cell cancer.